Free Trial
NASDAQ:CNAT

Conatus Pharmaceuticals (CNAT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.19
$0.19
50-Day Range
$0.56
$1.34
52-Week Range
$0.23
$1.07
Volume
222 shs
Average Volume
1.28 million shs
Market Capitalization
$6.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CNAT stock logo

About Conatus Pharmaceuticals Stock (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

CNAT Stock News Headlines

See More Headlines
Receive CNAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2020
Today
6/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNAT
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-11,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.72 million
Book Value
$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.30 million
Optionable
Not Optionable
Beta
1.84
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Steven J. Mento (Age 67)
    Co-Founder, Pres, CEO & Director
  • Dr. Keith W. Marshall MBA (Age 51)
    Ph.D., Exec. VP, COO & CFO
  • Dr. David T. Hagerty (Age 64)
    Exec. VP of Clinical Devel.
  • Dr. Alfred P. Spada (Age 61)
    Co-Founder, Exec. VP of R&D and Chief Scientific Officer
  • Mr. Alan R. Engbring
    Exec. Director of Investor Relations & Corp. Communications

CNAT Stock Analysis - Frequently Asked Questions

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%.

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN).

This page (NASDAQ:CNAT) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners